Johnson & Johnson (NYSE:JNJ) is Levin Capital Strategies L.P.’s 6th Largest Position

Levin Capital Strategies L.P. boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 213,172 shares of the company’s stock after acquiring an additional 1,390 shares during the quarter. Johnson & Johnson accounts for 2.9% of Levin Capital Strategies L.P.’s holdings, making the stock its 6th largest position. Levin Capital Strategies L.P.’s holdings in Johnson & Johnson were worth $30,829,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently bought and sold shares of the stock. Sharkey Howes & Javer raised its position in Johnson & Johnson by 47.4% during the fourth quarter. Sharkey Howes & Javer now owns 2,375 shares of the company’s stock valued at $344,000 after acquiring an additional 764 shares in the last quarter. Sherman Asset Management Inc. purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $361,000. Onefund LLC increased its position in shares of Johnson & Johnson by 2.8% in the fourth quarter. Onefund LLC now owns 6,497 shares of the company’s stock valued at $940,000 after buying an additional 174 shares in the last quarter. Richard W. Paul & Associates LLC increased its position in shares of Johnson & Johnson by 1.5% in the fourth quarter. Richard W. Paul & Associates LLC now owns 6,567 shares of the company’s stock valued at $950,000 after buying an additional 100 shares in the last quarter. Finally, Metis Global Partners LLC increased its position in shares of Johnson & Johnson by 1.4% in the fourth quarter. Metis Global Partners LLC now owns 140,714 shares of the company’s stock valued at $20,350,000 after buying an additional 1,956 shares in the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $167.08 on Tuesday. The stock’s fifty day moving average is $151.33 and its two-hundred day moving average is $156.08. The firm has a market capitalization of $402.26 billion, a P/E ratio of 25.12, a price-to-earnings-growth ratio of 2.56 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the prior year, the company posted $2.29 EPS. The company’s quarterly revenue was up 5.3% on a year-over-year basis. On average, research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 2.97%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Raymond James cut their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Leerink Partners lowered their price target on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Finally, Wells Fargo & Company lowered their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research note on Thursday, January 23rd. Nine analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Insider Activity

In other news, Director Mark A. Weinberger acquired 1,000 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The shares were purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.